Eltrombopag Olamine

Generic Name

Eltrombopag-olamine

Other Names

• Promacta
• Revolade

Drug Class

• Thrombopoietin receptor agonist

Chemical Formula

C29H34N4O6S

Molecular Weight

578.67 g/mol

Mechanism of Action

• Stimulates the proliferation and differentiation of megakaryocytes, leading to increased platelet production.

Indications

• Treatment of thrombocytopenia in patients with chronic immune thrombocytopenia (ITP)
• Treatment of thrombocytopenia in patients with chronic hepatitis C infection to allow the initiation and maintenance of interferon-based therapy

Common Dosage Forms

• Tablets

Typical Dosage

• 50 mg once daily

Pediatric Dosage

• Dosing based on weight and age, consult pediatric hematologist

Geriatric Dosage

• No specific dosage adjustment needed

Side Effects

• Headache
• Nausea
• Diarrhea
• Increased liver enzymes
• Myalgia
• Asthenia

Contraindications

• Hypersensitivity to eltrombopag
• Patients with a history of thrombosis

Pregnancy Category

• C - Risk cannot be ruled out

Lactation Safety

• Unknown, use caution

Drug Interactions

• Avoid concurrent use with strong CYP2C8 inhibitors or inducers
• May interact with anticoagulants and antiplatelet agents

Overdose Symptoms

• Risk of thrombosis
• Monitor platelet counts and manage symptoms

Antidote for Overdose

• No specific antidote, manage symptoms and consider platelet transfusion if necessary

Storage Conditions

• Store at room temperature away from moisture and heat

Pharmacokinetics

• Absorption: Well absorbed after oral administration
• Distribution: Highly bound to plasma protein
• Metabolism: Metabolized in the liver by CYP1A2 and CYP2C8
• Excretion: Primarily excreted in feces

Precautions

• Monitor platelet counts regularly during therapy
• Use with caution in patients with a history of liver disease

Warnings

• Risk of hepatotoxicity
• Risk of thromboembolic events

Others

• It is important to assess the patient's platelet counts before initiating therapy and regularly during treatment.